Category Archives: Neuroscience

The Challenges of Studying Marijuanas Effects on the Heart and Brain – Neuroscience News

Summary: Researchers identify problem areas they face in studying the effects of cannabis on the brain and heart function.

Source: American Heart Association

Over the past decade, marijuana use, both recreational and medicinal, has grown as state governments across the U.S. have legalized its use. But while it might be legal for adults to light up, the question of whether it is harmful or helpful in many cases remains unanswered.

Researchers say the truth is complicated.

Though it has been studied for decades, much remains unknown about how marijuana, or cannabis, affects heart and brain health. And there are significant challenges to finding clear answers.

The evidence that has been emerging from animal models show ramifications in the brain and in the heart, but the data for humans is more murky, said Dr. Fernando Daniel Testai, a neurologist at the University of Chicago Department of Neurology and Rehabilitation. Testai was lead author on an American Heart Associationscientific statementlast year that detailed whats known, and not known, about marijuanas effects on brain health.

So many things factor into the equation, said Staci Gruber, an associate professor of psychiatry at Harvard Medical School in Boston. She oversees the Marijuana Investigations for Neuroscientific Discovery (MIND) program at McLean Hospital in Belmont, Massachusetts, which studies the effects of medical marijuana on clinical and cognitive measures, as well as brain structure and function and quality of life.

Differences in how people use marijuana, concentrations of the products they use, the active ingredients they contain, how often they use them and for how long, as well as age all may play a role in determining how health is affected, Gruber said. Its up to researchers to drill down in each of these areas, but legal, ethical and other hurdles make it difficult to do so.

More than 48 million people in the U.S. over the age of 12 reported using marijuana in 2019, according to theSubstance Abuse and Mental Health Administration. Thats roughly 18% of the population, which is up from 11% two decades ago.

Also known as pot or weed, marijuana can be used recreationally or formedicinal purposes, such as to reduce nausea or ease chronic pain in people with cancer. It can be smoked in cigarette form or through pipes or water pipes, vaped, or infused into baked goods, gummy candies or drinks.

Its compounds can be extracted to make oils and concentrates, which can also be vaped or smoked.Little is knownabout the safety of one method compared to another, though there is evidence the combustion from smoking marijuana can be harmful.

Gruber said some of the confusion stems from what people mean when they use the word marijuana. Marijuana refers to the dried flowers, leaves, stems and seeds of the cannabis plant, which contains more than 100 chemical compounds.

The two most recognized are tetrahydrocannabinolTHCresponsible for the plants mind-altering effects, and cannabidiolCBDwhich does not produce a high but has been used to treat pediatric seizure disorders, anxiety, pain and inflammation.

We often use the terms marijuana or cannabis to describe anything that comes from the plant, but different compounds from the plant have different effects, Gruber said.

When discussing health impacts, its also important to distinguish between recreational and medicinal use, she said. Recreational users tend to look for high THC content in the products they use. Medical users may or may not. They dont typically want to get high, but want to alleviate symptoms so they can do everyday things like go to the store and remember why they are there.

Some studies suggestchronic, heavy recreational use can harm cognitive functionespecially if that use begins during adolescence. But research shows adult medical cannabis patients may experience some cognitive benefits. Gruber was the senior author of astudy published 2018 in theFrontiers of Pharmacologyjournalthat showed people who used medical cannabis experienced improvements in executive function over time, with no deficits in verbal learning or memory.

There also are differences in how different types of use affect heart health.

Though the high levels of THC exposure from recreational usemay cause a rise in blood pressure, said Gruber, astudy last year in Israelfound people age 60 and older who used medical marijuana for three months had a reduction inblood pressure.

A 2020scientific statementfrom the AHA saidobservational studieshave linkedmarijuana useto an increased risk of heart attacks, atrial fibrillation and heart failure, but acknowledged its impact on the heart and blood vessels was not well understood due to a lack of adequate research.

A study that directly compares the effects of medical marijuana use to recreational use would help, Testai said. As would a clearer definition of what chronic, heavy recreational use really means.

Most studies measure exposure to marijuana based on self-reported use, he said. Theres no objective data for how much people are consuming.

Another challenge is people who use it recreationally may use other drugs or substances, such as cigarettes or other mind-altering drugs. That makes it difficult to tease out which impacts come from which substances, Testai said.

How often a person uses marijuana, how much they use and for how long matters, Gruber said. For example, people may initially experience a rapid heart rate, called tachycardia, from products containing THC. But consistent use may result in tolerance to that effect, often after a few days or weeks.

In clinical studies, researchers measure and control what people are consuming. But because the federal government still classifies marijuana as a schedule 1 substance, meaning it is considered to have a high potential for abuse, researchers face tough restrictions on the products they can give study participants.

The National Institute on Drug Abuse Drug Supply Program provides marijuana for research purposes, Gruber said. But research-grade marijuana isnt what people are consuming in their homes.

Unlike alcohol, which is pretty straightforward, cannabis is many different things, she said. She asks people who use recreational marijuana in her observational studies to submit samples of the products they use most often so they can be analyzed to better measure whats going into their bodies.

Age also plays an important role, Gruber said. Evidence suggests using marijuana during key periods of brain development may harm cognition more than it would if use began in adulthood.

Testai said researchers face another obstacle: the inability to assign a control group to placebo.

The most fundamental or clear way to practice research is a randomized study with placebo, he said. But with marijuana, there is no way you can actually mask its effect. Doing high-quality research in this field is confounded by the waymarijuanaworks, not to mention the ethics.

Until theres a better solution, said Gruber, researchers have to be creative thinkers. We have to try to capture observational data as closely and rigorously as we can as well as conduct empirically sound clinical trials.

Author: Laura WilliamsonSource: American Heart AssociationContact: Laura Williamson American Heart AssociationImage: The image is in the public domain

See the article here:
The Challenges of Studying Marijuanas Effects on the Heart and Brain - Neuroscience News

Insights on the Mental Health Apps Global Market to 2027: Featuring Sanvello Health, Flow Neuroscience and Youper Among Others – GlobeNewswire

Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Global Mental Health Apps Market Size, Share & Industry Trends Analysis Report By Application, By Platform Type (iOS, Android, and Others), By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The Global Mental Health Apps Market size is expected to reach $10.2 billion by 2027, rising at a market growth of 16.3% CAGR during the forecast period.

The market is rising because individuals become more aware of the significance of mental health and as a result of the debut of several mental wellness applications. The advent of significant health campaigns such as the Campaign Against Living Miserably (CALM) to promote awareness about mental health, as well as the rising use of connected gadgets among the youthful population, is driving up market value.

Furthermore, poor work-life balance and eating habits, social isolation, hectic schedules, and relationship issues are all key factors that are raising the incidence of mental illness among people all over the world, particularly in developed and emerging nations. Moreover, it is expected that increased awareness among people in developing economies, as well as the creation of updated and advanced featured applications, is expected to provide prospective prospects over the forecast period.

Therapy applications were already gaining traction among people dealing with issues ranging from stress to serious mental disease when the COVID-19 outbreak struck. When offices turned virtual, they carved out a niche for themselves in the mental health industry. While certain apps, such as Talkspace and Betterhelp, pair you with a certified therapist, a large chunk of the industry has gone completely humanless. Friendly chatbots provide cognitive behavioural therapy; mood trackers remind bipolar disorder patients to keep track of their mood; and apps for treating post-traumatic stress disorder claim to assist people to get over acute bouts by guiding them through deep breathing exercises.

COVID-19 Impact AnalysisThe COVID-19 pandemic resulted in a spike in mental health app downloads as well as greater awareness of mental health as a serious concern. As a result, the digital health and mobile health sectors have shown significant growth potential. According to ORCHA (Organization for the Review of Care and Health Applications) data, mental health app downloads in the United Kingdom climbed by about 200 percent from summer 2019 to summer 2020.

Due to the many advantages offered by these apps in treating mental health conditions like as stress, sadness, and anxiety, the market for mental health apps saw a rise in adoption during the COVID-19 pandemic. As per Sensor Tower statistics, the top mental wellness apps saw a combined download increase of about 2 million in April 2020 compared to January.

Market Growth Factors:

High inclination towards virtual therapiesFor persons suffering from depression, there are literally thousands of apps available. Some are based on exchanging messages or making phone calls with doctors, while others provide recommendations, self-guided mood training programmes, and gamification components. MoodTools, an anti-depression app, treats depression carefully and has a suicide safety plan in place in the event of a crisis. There are additional apps for treating diseases like schizophrenia and psychoses, in addition to depression apps. Doctors, on the other hand, argue that apps for people with psychological illnesses are best used as a supplement to regular therapy; unlike apps for mentally healthy people, applications for persons with psychological disorders must include doctors.

Increasing stress level among individualsPeople's or society's stress levels are rising as a result of causes such as substance addiction, increased mental health awareness in recent years, and fewer social connections. In addition, over time, the use of advanced linked technologies such as physician-recommended mental health apps, wearables, and self-assessment awareness gadgets has grown. As a result, demand for mental health apps is predicted to increase in recent years. Psychotherapists, other doctors, psychiatrists, and clinical psychologists can use mental apps to examine and monitor their patients' mental health. As a result, the market for mental health applications is fueled by the adoption of such apps by experts.

Market Restraining Factors

Privacy and research concernsAlthough there is research on using mobile apps in conjunction with therapy, there is little research about how these apps are developed, with one exception: if the apps are produced by the federal government, such as the Substance Abuse and Mental Health Administration (SAMHSA) or the US Department of Veteran's Affairs (VA)/Department of Defense (DOD), they usually include app development information. There are two types of mental health apps for mobile devices: passive and active. Active apps necessitate direct patient input, like the completion of mood logs, self-symptom ratings, and the recording of personal experiences. Without the patient or provider's knowledge, passive apps can access information and collect data using smartphone functions like GPS. Though it may be advantageous, some people may object to the possible invasion of privacy that such data collection entails.

Application OutlookBased on Application, the market is segmented into Depression & Anxiety Management, Meditation Management, Stress Management, Wellness Management, and Others. The stress management segment witnessed a promising revenue share in the mental health apps market in 2020. The increasing prevalence of stress and related diseases, as well as the growing usage of applications that aid in stress reduction and management, are driving the segment's rise over the forecast period.

Platform Type OutlookBased on Platform Type, the market is segmented into iOS, Android, and Others. In 2020, the iOS segment procured the highest revenue share in the mental health apps market. The growing acceptance of iOS among customers can be linked to the rise of the iOS category. The market share of iOS in the United Kingdom climbed from 47 percent in Q3 2020 to 51.6 percent in Q3 2021, according to data published by Business of Apps in 2021. As a result, such examples show that the segment will grow in the next years.

Regional OutlookBased on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the mental health apps market with the maximum revenue share in 2020. The market is being fueled by prominent factors such as the increasing adoption of smartphones, advancements in coverage networks, and increased penetration of the internet and social media. Smartphone usage in the North American region was around 80% in 2020, according to the GSMA's The Mobile Economy Report 2021, and is anticipated to reach 85 percent by 2025.

Recent Strategies Deployed in Mental Health Apps Market

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/u6thhb

View original post here:
Insights on the Mental Health Apps Global Market to 2027: Featuring Sanvello Health, Flow Neuroscience and Youper Among Others - GlobeNewswire

Artificial Intelligence to Assess Dementia Risk and Enhance the Effectiveness of Depression Treatments – Neuroscience News

Summary: Using MEG data, a new AI algorithm called AI-MIND is able to assess dementia risk and the potential effectiveness of treatments for depression, researchers say.

Source: Aalto University

The human brain consists of some 86 billion neurons, nerve cells that process and convey information through electrical nerve impulses.

Thats why measuring neural electrical activity is often the best way to study the brain, says Hanna Renvall. She is Aalto University and HUS Helsinki University Hospital Assistant Professor in Translational Brain Imaging and heads the HUS BioMag Laboratory.

Electroencephalography, or EEG, is the most used brain imaging technique in the world. Renvalls favorite, however, is magnetoencephalography or MEG, which measures the magnetic fields generated by the brains electrical activity.

MEG signals are easier to interpret than EEG because the skull and other tissues dont distort magnetic fields as much. This is precisely what makes the technique so great, Renvall explains.

MEG can locate the active part of the brain with much greater accuracy, at times achieving millimeter-scale precision.

An MEG device looks a lot like bonnet hairdryers found in hair salons. The SQUID sensors that perform the measurements are concealed and effectively insulated inside the bonnet because they only function at truly freezing temperatures, close to absolute zero.

The worlds first whole-head MEG device was built by a company that emerged from Helsinki University of Technologys Low Temperature Laboratoryand is now the leading equipment manufacturer in this field.

MEG plays a major role in the European Unions new AI-Mind project, whose Finnish contributors are Aalto and HUS. The goal of the 14-million project is to learn ways to identify those patients, whose dementia could be delayed or even prevented.

For this to happen, neuroscience and neurotechnology need help from artificial intelligence experts.

Fingerprinting the brain

Dementia is a broad-reaching neural function disorder that significantly erodes the sufferers ability to cope with everyday life. Some 10 million people are afflicted in Europe, and as the population ages this number is growing. The most common illness that causes dementia is Alzheimers disease, which is diagnosed in 7080% of dementia patients.

Researchers believe that communication between neurons begins to deteriorate well before the initial clinical symptoms of dementia present themselves. This can be seen in MEG dataif you know what to look for.

MEG is at its strongest when measuring the brains response to stimuli like speech and touch that occur at specific moments and are repetitive.

Interpreting resting-state measurements is considerably more complex.

Thats why the AI-Mind project uses a tool referred to as the fingerprint of the brain. It was created when Renvall and Professor Riitta Salmelin and her colleagues began to investigate whether MEG measurements could detect a persons genotype.

More than 100 sibling pairs took part in the study that sat subjects in an MEG, first for a couple of minutes with their eyes closed and then for a couple of minutes with their eyes open. They also submitted blood samples for a simple genetic analysis.

When researchers compared the graphs and genetic markers, they noticed that, even though there was substantial variance between individuals, siblings graphs were similar.

Next, Aalto University Artificial Intelligence Professor Samuel Kaskis group tested whether a computer could learn to identify graph sections that were as similar as possible between siblings while also being maximally different when compared to other test subjects.

The machine did itand more, surprisingly.

It learned to distinguish the individual perfectly based on just the graphs, irrespective of whether the imaging had been performed with the test subjects eyes open or closed, Hanna Renvall says.

For humans, graphs taken with eyes closed or open look very different, but the machine could identify their individual features. Were extremely excited about this brain fingerprinting and are now thinking about how we could teach the machine to recognize neural network deterioration in a similar manner.

Risk screening in one week

A large share of dementia patients are diagnosed only after the disorder has already progressed, which explains why treatments tend to focus on managing late-stage symptoms.

Earlier research has, however, demonstrated that many patients experience cognitive deterioration, such as memory and thought disorders, for years before their diagnosis.

One objective of the AI-Mind project is to learn ways to screen individuals with a significantly higher risk of developing memory disorders in the next few years from the larger group of those suffering from mild cognitive deterioration.

Researchers plan to image 1,000 people from around Europe who are deemed at risk of developing memory disorders and analyze how their neural signals differ from people free from cognitive deterioration. AI will then couple their brain imaging data with cognitive test results and genetic biomarkers.

Researchers believe this method could identify a heightened dementia risk in as little as a week.

If people know about their risk in time, it can have a dramatic motivating effect, says Renvall, who has years of experience of treating patients as a neurologist.

Lifestyle changes like a healthier diet, exercise, treating cardiovascular diseases and cognitive rehabilitation can significantly slow the progression of memory disorders.

Better managing risk factors can give the patient many more good years, which is tremendously meaningful for individuals, their loved ones and society, as well, Renvall says.

Identifying at-risk individuals will also be key when the first drugs that slow disease progression come on the market, perhaps in the next few years. Renvall says it will be a momentous event, as the medicinal treatment of memory disorders has not seen any substantial progress in the last two decades.

The new pharmaceuticals will not suit everybody, however.

These drugs are quite powerful, as are their side effectsthats why we need to identify the people who can benefit from them the most, Renvall emphasizes.

Zapping the brain

Brain activity involves electric currents, which generate magnetic fields that can be measured from outside the skull.

The process also works in the other direction, the principle on whichtranscranial magnetic stimulation(TMS) is based. In TMS treatments, a coil is placed on the head to produce a powerful magnetic field that reaches the brain through skin and bone, without losing strength. Themagnetic fieldpulse causes a short, weak electric field in the brain that affects neuron activity.

It sounds wild, but its completely safe, says Professor of Applied Physics Risto Ilmoniemi, who has been developing and using TMS for decades.

The strength of the electric field is comparable to the brains own electric fields. The patient feels the stimulation, which is delivered in pulses, as light taps on their skin.

Magnetic stimulation is used to treatsevere depressionand neuropathic pain. At least 200 million people around the world suffer from severe depression, while neuropathic pain is prevalent among spinal injury patients, diabetics and multiple sclerosis sufferers. Pharmaceuticals provide adequate relief to only half of all depression patients; this share is just 30% in the case of neuropathic pain sufferers.

How frequently pulses are given is based on the illness being treated. For depression, inter-neuron communication is stimulated with high-frequency pulse series, while less frequent pulses calm patients neurons for neuropathic pain relief.

Stimulation is administered to the part of the brain where, according to the latest medical science, the neurons tied to the illness being treated are located.

About half of treated patients receive significant relief from magnetic stimulation. Ilmoniemi believes this could be much higherwith more coils and the help of algorithms.

One-note clanger to concert virtuoso

In 2018, the ConnectToBrain research project headed by Ilmoniemi was granted 10 million in European Research Council Synergy funding, the first time that synergy funds were awarded to a project steered by a Finnish university. Top experts in the field from Germany and Italy are also involved.

The goal of the project is to radically improve magnetic stimulation in two ways: by building a magnetic stimulation device with up to 50 coils and by developing algorithms to automatically control the stimulation in real time, based on EEG feedback.

Ilmoniemi looks to the world of music for a comparison.

The difference between the new technology and the old is analogous to a concert pianist playing two-handed, continuously fine-tuning their performance based on what they hear, rather than hitting a single key while wearing hearing protection.

Researchers have already used a two-coil device to demonstrate that an algorithm can steer stimulation in the right direction ten times faster than even the most experienced expert. This is just the beginning.

A five-coil device completed last year covers an area of ten square centimeters of cortex at a time. A 50-coil system would cover both cerebral hemispheres.

Building this kind of device involves many technical challenges. Getting all these coils to fit around the head is no easy task, nor is safely producing the strong currents required.

Even once these issues are resolved, the hardest question remains: how can we treat the brain in the best possible way?

What kind of information does the algorithm need? What data should instruct its learning? It is an enormous challenge for us and our collaborators, Ilmoniemi says thoughtfully.

The project aims to build one magnetic stimulation device for Aalto, another for the University of Tbingen in Germany and a third for the University of Chieti-Pescara in Italy. The researchers hope that, in the future, there will be thousands of such devices in operation around the world.

The more patient data is accumulated, the better the algorithms can learn and the more effective the treatments will become.

Quantum optics sensors could revolutionize how we read neural signals

Professor Lauri Parkkonens working group is developing a new kind of MEG device that adapts to the head size and shape and utilizes sensors based onquantum optics. Unlike the SQUID sensors currently employed in MEG, they do not need to be encased in a thick layer of insulation, enabling measurements to be taken closer to the scalp surface. This makes it easier to perform precise measurements on children and babies especially.

The work has progressed at a brisk pace and yielded promising results: measurements made with optical sensors are already approaching the spatial accuracy of measurements made inside the cranium.

Parkkonen believes that a MEG system based on optical sensors could also be somewhat cheaper and more compact and thus easier to place than traditional devices; such a MEG system could utilize a person-sized magnetic shield instead of a large shielded room as the conventional MEG systems do.

This would bring it into reach of more researchers and hospitals.

Author: Minna HlttSource: Aalto UniversityContact: Minna Hltt Aalto UniversityImage: The image is in the public domain

Excerpt from:
Artificial Intelligence to Assess Dementia Risk and Enhance the Effectiveness of Depression Treatments - Neuroscience News

Measuring Natures Effects on Physical and Mental Health – Neuroscience News

Summary: Spending time enjoying the great outdoors improves both physical and mental health. Researchers say more interventions need to be taken to get people to spend time enjoying nature.

Source: Texas A&M

A study recently published inBMC Psychologyoutlines two scales created to measure factors related to time spent in nature, a first step in exploring how this affects health and well-being.

The scales were developed by a multidisciplinary team led byJay Maddock, professor in the Department of Environmental and Occupational Health at theTexas A&M University School of Public Health.

A body of evidence has shown that time spent in nature, or TSN, is associated with physical and mental health, yet most American adults spend very little time in green or natural spaces. Two strong predictors of health behaviors are self-efficacy and intentions.

However, scales to measure these factors have not yet been developed and are needed to create effective, evidence-based interventions to increase TSN.

The researchers used a nine-phase procedure to construct, refine and test the scales. The first phase identified self-efficacy and intentions as the factors that would be measured by the scales. Self-efficacy was defined as a persons confidence in his or her ability to take action and to persist in that action despite obstacles or challenges pertaining to spending time in nature.

Next, Intentions were defined as planning to engage in certain nature-related behaviors over the next three months. The first phase also involved initial generation of items to include in a survey to measure these factors.

Respondents were asked how confident they were that they could spend at least two hours per week in green or natural spaces under conditions including weather, stress, accessibility, scheduling or costs. They also were asked if they intended to participate in nature-related activities such as going outdoors, hiking or visiting parks in the next three months.

The survey was administered to a nationwide sample of more than 2,000 adults.

Spending more time in nature was found to correlate with both self-efficacy and intentions, suggesting that future interventions to improve TSN should have increasing confidence to spend time in nature as a goal.

Both factors negatively correlated with age, indicating diminishing confidence that could be related to mobility or safety concerns that increase as adults age.

Male respondents had higher self-efficacy than female respondents, a finding that agrees with other research showing that women are less likely to participate in recreational activities in nature despite showing a preference for doing so.

Development of the scales is just the first step of what the researchers hope will be a series of studies with the ultimate goal of finding ways to improve health and well-being through increased TSN.

Were working on developing a whole suite of measures, Maddock said. Once those are done, were going to be looking to develop theory-based interventions to increase time spent in nature.

Author: Rae Lynn MitchellSource: Texas A&MContact: Rae Lynn Mitchell Texas A&MImage: The image is in the public domain

Original Research: Open access.Development and validation of self-efficacy and intention measures for spending time in nature by Jay Maddock et al. BMC Psychology

Abstract

Development and validation of self-efficacy and intention measures for spending time in nature

The purpose of this study was to develop and evaluate the reliability and validity of self-efficacy and intentions measures for time spent in nature (TSN). TSN is related to improvement in psychological well-being and health, yet most American adults spend very little time in such settings. Theory-based interventions have been effective in increasing physical activity, a related behavior, and may be one mechanism to increase TSN. Self-efficacy and intentions have been shown to be strong predictors of health behaviors and are used across several theories. However, scales to measure these factors have not yet been developed and are needed to facilitate effective interventions.

TSN self-efficacy and intentions scales were developed using a sequential nine-step procedure: identification of the domain and item generation; content validity; pre-testing of questions; sampling and survey administration; item reduction; extraction of factors; tests of dimensionality; tests of reliability; and tests of validity. The 14-member multidisciplinary, researcher and practitioner investigative team generated 50 unique items for self-efficacy and 24 unique items for intentions. After subjecting items to content validity and pre-testing, item sets were reduced to 21 assessing self-efficacy and nine assessing intentions. A nationwide sample of 2109 adult participants (49.7% female, Mean Age=58.1; 59.8% White, 18.4% Hispanic, 13.3% Black) answered these items via an on-line survey.

Using split-half measures, principal components analysis indicated a one-factor solution for both scales. The factor structure was upheld in confirmatory factor analyses and had high internal consistency (=.93 self-efficacy; .91 intentions). The scales were moderately correlated with each other (r=.56,p<.001) and were strongly related to TSN with large effect sizes (eta2>.20).

The study resulted in reliable and valid self-efficacy (14 items) and intentions (8 items) scales that can be used to develop future theory-based interventions to increase TSN and thereby improve population health.

Continued here:
Measuring Natures Effects on Physical and Mental Health - Neuroscience News

Windows to the Soul: Pupils Reveal Aphantasia The Absence of Visual Imagination – Neuroscience News

Summary: People who experience visual imagination have pupillary responses that optimize the amount of light hitting the retina and change in response to imagined items. This pupillary response does not occur in those with aphantasia.

Source: University of New South Wales

The study, led by researchers from UNSW Sydney andpublished ineLife, found that the pupils of people with aphantasia did not respond when asked to imagine dark and light objects, while thosewithoutaphantasiadid.

To first gauge the pupillary reflex of non-aphantasic people, the researchers sought 42 study participants, self-reported as having a visual imagination, and fitted them with glasses to track their eye movements and pupil sizes.

Participants were then exposed to bright or dark shapes against a grey background, which predictably evoked pupillary constriction in response to bright shapes (comparable to looking up at a bright sky) and pupillary dilation in response to dark shapes (after switching a light off).

Next, to test visual imagery the minds capacity to visualise objects participants were asked to simply imagine those same light or dark shapes (with their eyes open, for their pupils to be tracked) and subsequently report the vividness of that imagery.

The researchers found that even in response toimaginedbright and dark shapes, the participants pupils still constricted and dilated appropriately, a pupillary response that was larger in those reporting greater imagery vividness.

The pupillary reflex is an adaption that optimises the amount of light hitting the retina, says Professor Joel Pearson, senior author on the paper.

And while it was already known that imagined objects can evoke so-called endogenous changes in pupil size, we were surprised to see more dramatic changes in those reporting more vivid imagery. This really is the first biological, objective test for imagery vividness.

Testing for a lack of imagination

Finally, with the link between visual imagery and pupillary response established, the researchers sought to test the effect in aphantasic individuals. The researchers repeated the study with 18 participants self-reporting aphantasia.

Exposing participants to bright and dark shapes, the researchers found that aphantasic individuals exhibited the same pupillary response as the general population: constriction to bright, dilation to dark.

However, during the studys second component where participants were asked to visualise those same shapes, the pupillary response of aphantasic individuals did not significantly differ in response to imagined dark versus imagined bright objects.

One of the problems with many existing methods to measure imagery is that they are subjective, that is to say they rely on people being able to accurately assess their own imagery. Our results show an exciting new objective method to measure visual imagery, says Prof Pearson, and the first physiological evidence of aphantasia. With over 1.3 million Australians thought to have aphantasia, and 400 million more internationally, we are now close to an objective physiological test, like a blood test, to see if someone truly has it.

To ensure the aphantasic participants were really attempting imagery, the researchers included a further experimental condition, requesting aphantasic individuals to visualise four shapes, instead of one.

While the pupils of those with aphantasia showed no difference when imagining light versus dark objects, they did show a difference imagining one versus four objects, suggesting more mental effort, thereby negating an explanation of non-participation by aphantasic individuals.

Our pupils are known to get larger when we are doing a more difficult task, says Lachlan Kay, PhD candidate in the Future Minds Lab, UNSW.

Imagining four objects simultaneously is more difficult than imagining just one. The pupils of those with aphantasia dilated when they imagined four shapes compared to one, but did not change based on the whether the shapes were bright or dark. This indicated that the participants with aphantasia were indeed trying to imagine in this experiment, just not in a visual way.

The aphantasic pupil response to the four objects condition is also a really exciting finding, adds Prof Pearson, because for the first time we have strong biological evidence that those with aphantasia are really trying to create a mental image, putting to rest claims that they may simply not be attempting to create a mental image.

These findings are also really interesting in regard to memory and aphantasia, said Dr Rebecca Keogh, Postdoctoral research fellow based at Macquarie University and another author of the study. Our previous work has shown that aphantasic individuals are able to perform visual working memory tasks, remembering many images for a short period of time, without using visual imagery.

These findings further highlight the wide variability of the human mind that can often remain hidden until we ask someone about their internal experiences or invent new ways to measure the mind. It reminds us that just because I remember or visualise something one way, doesnt mean everyone does.

Whats next for aphantasia research? A look into the future

Next, Prof Pearson and his team at the Future Minds Lab plan to investigate how this new method could be scaled up and run online to allow a global, efficient and objective measurement of imagery and aphantasia.

This really is an exciting time. We are very close to having objective, reliable tests for extreme imagery, aphantasia and hyperphantasia (extremely strong visual imagery) that could be scaled up to run online for millions of people everywhere, says Prof Pearson.

We know that thinking in pictures or not affects the number of details in lifelong memories, how emotional we get when reading, and how we hold things in short term memory. This new method will allow us to understand the brain mechanisms of extreme imagery and the global implications for how we think, make decisions and feel.

Author: Jesse HawleySource: University of New South WalesContact: Jesse Hawley University of New South WalesImage: The image is in the public domain

Original Research: Open access.The pupillary light response as a physiological index of aphantasia, sensory and phenomenological imagery strength by Joel Pearson et al. eLife

Abstract

The pupillary light response as a physiological index of aphantasia, sensory and phenomenological imagery strength

The pupillary light response is an important automatic physiological response which optimizes light reaching the retina.

Recent work has shown that the pupil also adjusts in response to illusory brightness and a range of cognitive functions, however, it remains unclear what exactly drives these endogenous changes.

Here, we show that the imagery pupillary light response correlates with objective measures of sensory imagery strength. Further, the trial-by-trial phenomenological vividness of visual imagery is tracked by the imagery pupillary light response.

We also demonstrated that a group of individuals without visual imagery (aphantasia) do not show any significant evidence of an imagery pupillary light response, however they do show perceptual pupil light responses and pupil dilation with larger cognitive load.

Our results provide evidence that the pupillary light response indexes the sensory strength of visual imagery. This work also provides the first physiological validation of aphantasia.

Link:
Windows to the Soul: Pupils Reveal Aphantasia The Absence of Visual Imagination - Neuroscience News

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference – Yahoo Finance

BetterLife Pharma Inc.

VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (BetterLife or the Company) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract on the preclinical data on anti-depressant activity of its lead compound 2-bromo-LSD (BETR-001) was accepted for presentation at the upcoming Canadian Association for Neuroscience (CAN) Conference, being held May 12-15 in Toronto, Canada. The study, led by Dr. Vern Lewis, is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience. This collaboration is also supported by the Mitacs Accelerate program.

At CAN, Dr. Lewis will present preclinical data demonstrating the neural plasticity-promoting and anti-depressant properties of BETR-001 from both in vitro and in vivo studies. The Dr. Lewis study demonstrated that treatment of rat embryonic cortical neurons with BETR-001 increases the structural complexity of neurons (dendrite growth and complexity) and therefore, provides evidence of neural plasticity activity of BETR-001. In certain measurements of structural plasticity in neurons, BETR-001 performed better than ketamine in this model.

BetterLife believes that BETR-001 is an uniquely positioned LSD derivative with the potential to be as effective as LSD in various neuro-psychiatric and neurological disorders without the burden of being hallucinogenic. Because of its non-hallucinogenic nature, BETR-001 will not have all the LSD requirements of administration in specialized clinics under special treatment protocols, the LSD controlled substance regulatory issues which impact manufacturing, distribution and patient access, and the overall associated high treatment costs for all these parameters. BETR-001 is protected by BetterLifes composition, method-of-use, synthesis and formulation patents (issued & provisional).

About BetterLife Pharma

Story continues

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLifes synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLifes pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

For further information, please visit BetterLife Pharma.

About the Department of Neuroscience at Carleton University

Carleton Neuroscience has an international reputation for research on stress and its effects on brain functioning and mental health. The department has an interdisciplinary approach to understanding the emergence, prevention and treatment of mental and physical disorders.For more information, please visit http://www.carleton.ca/neuroscience.

Contact Information

David Melles, Investor Relations ManagerEmail: David.Melles@blifepharma.comPhone: 1-778-887-1928

Cautionary Note Regarding Forward-Looking Statements

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as will, may, should, anticipate, expects and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Companys expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

View original post here:
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference - Yahoo Finance

Drug Reduced Frequency of Breathing Pauses in Sleep Apnea – Neuroscience News

Summary: Sulthiame, a CA inhibitor drug, reduced the number of breathing pauses and promoted oxygenation during the night in sufferers of obstructive sleep apnea.

Source: University of Gothenburg

A new University of Gothenburg study has paved the way for the first drug treatment for sleep apnea. Compared to before receiving the treatment, breathing pauses decreased with on average more than 20 per hour for patients given the drug.

The treatment that has been tested is carbonic anhydrase (CA) inhibition, CA being an enzyme that serves to maintain a balance between carbonic acid and carbon dioxide in the body. Several drugs with CA inhibitory properties are already available on the market, and used for treatment of glaucoma, epilepsy and other disorders.

Previous research has not systematically tested whether CA inhibitors also might be used to treat obstructive sleep apnea. The current study was a randomized double-blind clinical trial, and 59 patients with moderate or severe sleep apnea completed it.

Patients were randomly assigned to two groups receiving either 400 or 200 mg of the CA inhibitor, and a third group (the control group) that received placebo. The study lasted for four weeks.

Fewer breathing pauses

The results show that, overall, the treatment reduced the number of breathing pauses and promoted oxygenation during the night. A few patients experienced side effects, such as headache and breathlessness, which were more common in those receiving the highest dose.

The study results together with established safety data of the drug sulthiame provide support for continued research on CA inhibition as a new potential treatment for obstructive sleep apnea.

Among the patients who received the higher dosage of the drug, the number of breathing pauses decreased by approximately 20 per hour. For just over a third of patients in the study, only half of their breathing pauses were left, and in one in five the number fell by at least 60 percent, says Jan Hedner, Professor of Pulmonary Medicine.

The fact that several approved drugs in the CA inhibitor category are available on the market makes fast-tracking development of an approved drug for sleep apnea practicable. The drug used in this clinical trial was sulthiame, which is sometimes used to treat epilepsy in children.

Treatment options needed

Today, treatment for a patient with sleep apnea is either an oral appliance therapy or a CPAP (Continuous Positive Airway Pressure) mask. Both help to maintain airway patency during sleep.

These therapy options take time to get used to and, since they frequently are perceived as intrusive or bulky. Insufficient user time is therefore common. If we develop an effective drug, it will therefore make life easier for many patients and, in the long run, potentially also save more lives, says Ludger Grote, Senior Lecturer at Sahlgrenska Academy, University of Gothenburg.

The German pharmaceutical company Desitin Arzneimittel GmbH funded the trial, and the results are published in the American Journal of Respiratory and Critical Care Medicine.

Author: Press OfficeSource: University of GothenburgContact: Press Office University of GothenburgImage: The image is in the public domain

Original Research: The findings will appear in American Journal of Respiratory and Critical Care Medicine

Visit link:
Drug Reduced Frequency of Breathing Pauses in Sleep Apnea - Neuroscience News

UCSF Aims To Re-Think Neuroscience Research With Its New Building – Forbes

The Joan and Sanford Weill Neurosciences Building at UCSF Mission Bay.

Modern day science tends to be highly interdisciplinary. It increasingly requires different technical topics, skills, and expertise to come together to solve complex and challenging problems and questions. The image of the isolated scientist working alone in their lab for periods on end, emerging only to share a great discovery with the world, is somewhat antiquated. To be sure, doing science even today still necessitates long periods of deep thinking, introspection, and figuratively (occasionally literally) banging your head against the wall. But the tangible output of ones efforts are almost always a piece that fits into a broader scientific context. Collaborators may be working on other parts of the same problem, with everyones work eventually converging into a coherent whole. Or a solution may only emerge as a byproduct of collective brainstorming or the sharing of ideas. All of this, is to say, requires much and very tangible human-human interactions.

The environments - the building, labs, and offices - on university campuses in which all of this research takes place more and more reflect the need to serve these requirements. Architecture, art, and science are progressively more intertwined. Science is, after all, a very social pursuit. The research and public spaces that make up modern universities can be spectacular.

This is the path the University of California San Francisco (UCSF) is attempting to take with the newly opened Joan and Sanford Weill Neurosciences Building. Located on their Mission Bay campus, at just under 283,000 square feet, the building brings together clinical and basic neuroscience treatment and research under one roof. The Departments of Neurology, Neurological Surgery, Psychiatry and Behavioral Sciences, and the Institute for Neurodegenerative Diseases, along with the Weill Institute for Neurosciences and the Neuroscience Graduate Program, will all be housed in this building.

To make this possible, Joan and Sanford Weill made a gift of $185 million to the university, the largest gift in UCSFs history and one of the largest such donations in the country intended to specifically support neuroscience.

Dr. Stephen Hauser, the Robert A. Fishman Distinguished Professor of Neurology and Director of the Weill Institute for Neurosciences, offered his thoughts on the vision for the building and what it will enable.

What was the intended vision for the building and what do you hope it will achieve? Both scientifically and societally.

S.H.: We envisioned the building as a place where patients with difficult brain diseases receive care, where scientists search for answers to these problems, where young people will be inspired to dedicate themselves to careers in research and care, and a building that will also be a magnet for the community to promote interest in neuroscience.

We also needed a building that radiates hope, that reflects the optimism that we feel for the future. More than 60,000 patients annually will be seen in the clinical center, and here a variety of decision support tools and displays for precision medicine have been developed to assist patients and clinicians in tracking individual disease trajectories, contextualizing an individuals function relative to others, and providing evidence-based decision support.

Another key theme was that by breaking down silos across disciplines - across scientific disciplines and even across institutions - we could accelerate research to find answers to terrible brain disorders that affect more than 1 billion people each year. As one example, the distinctions between neurologic and psychiatric disorders of the brain are largely accidents of history, and importantly the same research tools are increasingly used to understand these disorders.So we brought these together. Also, we needed to bring other scientific disciplines, such as engineering, data sciences and imaging sciences, into our neuroscience community to maximize the potential for discovery.

What is perhaps most central is that the research mission will focus on human neuroscience and real human disease.By bringing together outstanding clinician-researchers with basic scientists, ideas gained at the laboratory can rapidly be validated at the bedside, and vice versa. So, a facility that will stimulate this interaction is the secret sauce of the building.

Another goal for this building is to excite the wider community with the exhilarating progress in brain science.What could be more interesting or more important than thinking about how we think?The big ethical issues that are likely to face us in the coming years are by no means restricted to neuroscience, but its in neuroscience that many of these questions come into sharpest focus, whether it be questions of enhancing cognitive or motor skills, computer brain interfaces and the creation of machine-human chimeras, the privacy of our thoughts, or the appropriate use of neuroscience data by the legal system.The stuff of science fiction is soon to become real.

What makes this building, and the environment it will create, unique to do neuroscience research compared to other state of the art buildings at other institutions?

S.H.: I dont think that there is another facility anywhere in the world quite like this - anchored in a huge medical and neuroscience community, focused on the neuroscience of human beings and human disease, and that brings clinical care and clinical research on the real diseases under the same roof as the basic lab investigations.

What is unique about the building and the environment it will create that you anticipate will lead to work and results - e.g. discoveries, technologies - that could not be achieved outside that environment?

S.H.: One of the most exciting developments has been recognition from others who share this vision and have joined us in new partnerships. One superb example is the Weill Neurohub, a close partnership across the neurosciences between UCSF, the University of California Berkeley, and the University of Washington. Another is a large 10 year partnership recently launched with Genentech and Roche, the Alliance for Therapies in Neuroscience, to jointly work together on problems in brain science and development of therapeutics.

Mark Cavagnero, Founding Principal at Mark Cavagnero Associates, the architecture firm that designed the building, provided his perspective on what it took to physically design and build a space that fulfilled UCSFs vision.

MC: Dr. Hausers goals were numerous and complex, though interconnected. It is the interconnected nature of all these goals that gives the building its unique form and singular presence.

The first challenge was to plan and design a building that integrates both clinical care for patients and state of the art research labs for scientists. The ability for scientists to both see patients and participate in their research projects in the same building on the same day was pivotal. The building goals were to not just envision this new form of integrated clinical care and scientific research, but to create a new form of architectural expression which presents that sensibility to everyone who sees it. We needed to fully understand the goal of creating a destination building- a destination for patients, for scientists, for science itself. It was never considered a secure bunker for research, but always seen as a transparent center for ideas, ideas grounded in progress, care, and hope.

How did you balance the aesthetics of the building with its technical and scientific requirements?

M.C. In making a building that attracts young people to dedicate themselves to research and care careers and to be a magnet for the community in a way to promote neuroscience and to radiate hope- the building needed to be beautiful from every angle. I wanted the building to change its feel slightly depending on your vantage point, your angle of view. Beauty is timeless and its own source of wonderment and joy; so creating a building of beauty was a strong desire.

As we understood these goals more and more clearly, it became clear that the building needed to have a unique clarity to it. The building needed to express the rational permanence of science with the all-too- human dynamism of nature. Bringing science and nature, rational thought and human emotion into each space was our challenge. Bringing both sides of the brain into ones awareness of the environment seemed exciting to me, to simultaneously fulfill the needs for abstract thought and tactile perception and feeling.

The human nature of socialization, of impromptu meeting and spontaneous discussion was also discussed at length. Scientists of different background can meet over coffee, lunch, in a meeting room, in a lounge or on the roof terrace overlooking the campus. Excitement and research updates can be shared quickly and personally, with interaction made so easy. The human side of research, once again, is being given great priority. The screens temper the dry and wet labs only. The clinical care and social spaces where scientists mingle- all are clear and exposed to the community. The essential human quality of this endeavor is made manifest even if the research has a veil of protection over it.

The reception from the faculty occupying the new space has been positive. Dr. Riley Bove, Associate Professor of Neurology, expressed how this new environment will be transformational in allowing our work in digital and precision medicine to become a reality for patients seen in the neuropsychiatry clinics. Across our institution, there have been a number of pivotal studies validating the ability to digitally phenotype patients, remotely engage and monitor individuals, and apply complex algorithms to understand human behavior, imaging, and biosamples. To date, individuals including clinicians, engineers, psychologists, physicists, and geneticists have often worked in siloes, focusing on a specific tool, insight, or condition. The new Institute is an opportunity for researchers who have worked on siloed aspects of this research to come together and thread all the rich insights and data back into the clinic in simple, relevant formats, to impact clinical care.

For Dr. Mercedes Paredes, also an Associate Professor in the Department of Neurology, who studies perinatal brain development, a critical period immediately before and after birth that can impact neurodevelopmental disorders such as epilepsy or autism spectrum disorder, the buildingthat will bring diverse expertise in neuroscience includingleaders in cutting edge CRISPR technology, developmental bioinformatic gurus, and neuropathologists and neonatologists. She went on to explain how having this multidisciplinary perspective together will accelerate collaborationand discoveries across many fields. I also think it's special to have this adjacent to the clinical work, in the hopes that each side of the bench-clinic can inspireone another.

Dr. Edward Chang, Professor and Chair of the Department of Neurological Surgery said that the new building is an extraordinary environment for carrying out our researchonhuman brain neural computations. The generous natural light, high ceilings, and open space layout achieve a perfect balance.

Similar comments were made by the other departments who have faculty moving into the new building. Dr. MatthewW.State, Chair of the Department of Psychiatry and Behavioral Sciences said the buildingplaces the basic science of psychiatry literally in the heart of the outstanding UCSF neuroscience community.It advances our shared missionat UCSF of breaking down the arbitrary barriers that have historically separated psychiatry from neurology, neurosurgery and other medical and scientific fields that focusonthe brain. And for S. Andrew Josephson, Chair of Neurology, the newbuilding's combinationof laboratories, clinical research facilities, and computational centers combined with patient-based clinical care including state-of-the-art imaging and neuroinfusionpositions us to quickly translate discoveries into therapies for a group of disorders that urgently need solutions.

It is evident that the new building was architecturally and aesthetically carefully designed to allow the interaction of clinical and basic neuroscience research and care to take place in a harmonious way under one impressive space. It feels like science and medicine taking place literally inside a work of art. Of course, only time will tell how the new building and the work that will take place within will differ from other similar efforts at universities across the world - which no doubt provides challenging competition. Yet, the new UCSF building seems almost purposefully designed to allow the imagination and creativity of its occupants to thrive. Which is after all what is necessary to truly understand and treat the brain.

View post:
UCSF Aims To Re-Think Neuroscience Research With Its New Building - Forbes

Nettles receives award from Society for Neuroscience – The Source – Washington University in St. Louis – Washington University Record

Sabin Nettles, a graduate student in the Department of Neuroscience at the School of Medicine, received the Pre/Postdoctoral Next Generation Award from the Society for Neuroscience in recognition of her outreach work introducing neuroscience to young students through the Brain Discovery initiative.

Read more on the Department of Neuroscience website.

Excerpt from:
Nettles receives award from Society for Neuroscience - The Source - Washington University in St. Louis - Washington University Record

Researchers provide insight into how the brain multitasks while walking – URMC

New research turns the old idiom about not being able to walk and chew gum on its head. Scientists with the Del Monte Institute for Neuroscience at the University of Rochester have shown that the healthy brain is able to multitask while walking without sacrificing how either activity is accomplished.

David Richardson

This research shows us that the brain is flexible and can take on additional burdens, said David Richardson, an MD/PhD student in his fifth year in the Pathology & Cell Biology of Disease Program, and first author of the study recently published in the journal NeuroImage. Our findings showed that the walking patterns of the participants improved when they performed a cognitive task at the same time, suggesting they were actually more stable while walking and performing the task than when they were solely focused on walking.

During these experiments, researchers used a Mobile Brain/Body Imaging system, or MoBI, located in the Del Monte Institutes Frederick J. and Marion A. Schindler Cognitive Neurophysiology Lab. The platform combines virtual reality, brain monitoring, and motion capture technology. While participants walk on a treadmill or manipulate objects on a table, 16 high speed cameras record the position markers with millimeter precision, while simultaneously measuring their brain activity.

Example of image captured by MoBI.

The MoBI was used to record the brain activity of participants as they walked on a treadmill and were cued to switch tasks. Their brain activity was also recorded as they performed these same tasks while sitting. Brain changes were measured between the cued tasks and showed that during the more difficult the tasks the neurophysiological difference was greater between walking and sitting highlighting the flexibility of a healthy brain and how it prepares for and executes tasks based on difficulty level.

The MoBI allows us to better understand how the brain functions in everyday life, said Edward Freedman, Ph.D., lead author on the study. Looking at these findings to understand how a young healthy brain is able to switch tasks will give us better insight to whats going awry in a brain with a neurodegenerative disease like Alzheimers disease.

Edward Freedman, Ph.D.

Understanding how a young healthy brain can successfully walk and talk is an important start, but we also need to understand how these findings differ in the brains of healthy older adults, and adults with neurodegenerative diseases, said Richardson. The next stage is expanding this research to include a more diverse group of brains.

Additional authors include John Foxe, Ph.D., Kevin Mazurek, Ph.D., and Nicholas Abraham of the University of Rochester. This research was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Del Monte Institute for Neuroscience Pilot Program.

See the article here:
Researchers provide insight into how the brain multitasks while walking - URMC